Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine

NCT05897320 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT05897320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05897320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Recruiting
Start date
June 8, 2023
Completion date
August 31, 2027
Enrollment
315 (estimated)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

episodic migraine